Finasteride Decreases the Risk of Prostatic Intraepithelial Neoplasia

Journal of Urology

Volumn 178, Issue 1, 2007, Pages 107-110

  Thompson, Ian M ^a   Lucia, M Scott ^a   Redman, Mary W ^a   Darke, Amy ^a   La Rosa, Francisco G ^a   Parnes, Howard L ^a   Lippman, Scott M ^a   Coltman, Charles A ^a  

^a Southwest Oncology Group   (United States)

Author keywords

finasteride; prevention and control; prostate; prostatic neoplasms; risk

Indexed keywords

FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

ANALYTIC METHOD; ARTICLE; CANCER RISK; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS;

EID: 34250343027     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.03.012     Document Type: Article

References (26)

1. American Cancer Society. Cancer Facts and Figures 2006 (2006), American Cancer Society, Atlanta 13
2. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., and Thun M.J. Cancer statistics 2006. CA Cancer J Clin 56 (2006) 106
3. McNeal J.E., and Bostwick D.G. Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol 17 (1986) 64
4. Bostwick D.G., and Qian J. High-grade prostatic intraepithelial neoplasia. Mod Pathol 17 (2004) 360
5. Davidson D., Bostwick D.G., Qian J., Wollan P.C., Oesterling J.E., Rudders R.A., et al. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. J Urol 154 (1995) 1295
6. Emmert-Buck M.R., Vocke C.D., Pozzatti R.O., Duray P.H., Jennings S.B., Florence C.D., et al. Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res 55 (1995) 2959
7. Qian J., Bostwick D.G., Takahashi S., Borell T.J., Herath J.F., Lieber M.M., et al. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 55 (1995) 540814
8. Park S.J., Miyake H., Hara I., and Eto H. Predictors of prostate cancer on repeat transrectal ultrasound-guided systemic prostate biopsy. Int J Urol 10 (2003) 68
9. Shepherd D., Keetch D.W., Humphrey P.A., Smith D.S., and Stahl D. Repeat biopsy strategy in men with isolated prostatic intraepithelial neoplasia on prostate needle biopsy. J Urol 156 (1996) 460
10. Epstein J.I., and Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol 175 (2006) 820
11. Bostwick D.G., and Brawer M.K. Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer 59 (1987) 788
12. Steiner M.S., Raghow S., and Neubauer B.L. Selective estrogen receptor modulators for the chemoprevention of prostate cancer. Urology 57 (2001) 68
13. Nelson M.A., Reid M., Duffield-Lillico A.J., and Marshall J.R. Prostate cancer and selenium. Urol Clin North Am 29 (2002) 67
14. Steiner M.S., and Pound C.R. Phase IIA clinical trial to test the efficacy and safety of Toremifene in men with high-grade prostatic intraepithelial neoplasia. Clin Prostate Cancer 2 (2003) 24
15. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215
16. Qian J., Wollan P., and Bostwick D.G. The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma. Hum Pathol 28 (1997) 143
17. Sakr W.A., Billis A., Ekman P., Wilt T., and Bostwick D.G. Epidemiology of high-grade prostatic intraepithelial neoplasia. Scand J Urol Nephrol 205 suppl. (2000) 11
18. Clark L.C., and Marshall J.R. Randomized, controlled chemoprevention trials in populations at very high risk for prostate cancer: elevated prostate specific antigen and high-grade prostatic intraepithelial neoplasia. Urology 57 (2001) 185
19. Kelloff G.J., Boone C.W., Crowell J.A., Steele V.E., Lubet R., and Doody L.A. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials. J Cell Biochem 19 suppl. (1994) 1
20. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 16 (1998) 1371
21. Vogel V.G., Costantino J.P., Wickerham D.L., Cronin W.M., Cecchini R.S., Atkins J.N., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 295 (2006) 2727
22. Harlan S.R., Cooperberg M.R., Elkin E.P., Lubeck D.P., Meng M.V., Mehta S.S., et al. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol 170 (2003) 1804
23. Stanford J.L., Feng Z., Hamilton A.S., Gilliland F.D., Stephenson R.A., Eley J.W., et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 283 (2000) 354
24. Zietman A.L., DeSilvio M.L., Slater J.D., Rossi C.J., Miller D.W., Adams J.A., et al. Comparison of conventional-dose versus high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294 (2005) 1233
25. Unger J.M., Thompson Jr. I.M., LeBlanc M., Crowley J.J., Goodman P.J., Ford L.G., et al. Estimated impact of the Prostate Cancer Prevention Trial on population mortality. Cancer 103 (2005) 1375
26. Lotan Y., Cadeddu J.A., Lee J.J., Roehrborn C.G., and Lippman S.M. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. J Clin Oncol 23 (2005) 1911